Découvrez ici la liste des différentes études cliniques en cours classées par centre.
Etudes sponsorisées interventionnelles en cours:
Etudes sponsorisées non interventionnelles en cours:
Etudes académiques non interventionnelles en cours:
| Etudes Onco en cours | |||
| 1st line | |||
| Acronyme | Studies | Cancer | PI |
| BO29554 study (B-FAST) | A phase II/III multicentre study evaluating the efficacy and safety of multiple targeted therapies as treatments for patients with advanced or metastatic non-small cell lung cancer (NSCLC) harbouring actionable somatic mutations detected in blood (B-Fast: blood-first assay screening trial) | NSCLC (ROS+) A venir: BRAF V600+ | P.C |
| ADRIATIC (D933QC00001) | Phase III, randomised, double-blind, placebo-controlled, multi-centre study assessing the efficacy and safety of durvalumab or durvalumab and tremelimumab in patients with LD-SCLC who have not progressed following definitive, platinum-based, concurrent chemoradiation therapy (CRT) | SCLC limités post-chimioradio | T.P |
| ANAM 17-21 | A phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to evaluate the efficacy and safety of Anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced NSCLC | NSCLC cachexia | T.P |
| Zenith20 (Spectrum) (SPI-POZ-202) | Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20) (SPI-POZ-202) | NSCLC IV EGFR ou HER2 exon 20 inser/mut | T.P |
| CA209-73L | A Phase 3, Randomized, Open-Label Study to Compare Nivolumab Plus Concurrent Chemoradiotherapy (CCRT) followed by Nivolumab Plus Ipilimumab or Nivolumab plus CCRT Followed by Nivolumab vs CCRT followed by Durvalumab in Previously Untreated, Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA NSCLC) | NSCLC IIIA/B/C | TP |
| 2nd line | |||
| ImmunoSABR | Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer | NSCLC IV | X.G |
| AMG510 (20190009) | A Phase 3 Multicenter, Randomized, Open Label, Active-controlled, Study of AMG 510 Versus Docetaxel for the Treatment of Previously Treated Locally Advanced and Unresectable or Metastatic NSCLC Subjects With Mutated KRAS p.G12C | NSCLC KRAS p.G12C | ThP |
| ≥ 3rd line | |||
| ImmunoSABR | Phase II study examining the activity of L19-IL2 immunotherapy and stereotactic ablative radiotherapy in metastatic non-small cell lung cancer | NSCLC IV | X.G |
| Autres | |||
| Acronyme | Studies | Cancer | PI |
| EORTC: E2-Radiate 1811 | E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe | Tous cancers oligométa traités par Rth | XG |
| PACIFIC R D4194R00005 | First real-world data on unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy | NSCLC stage III with durvalumab post chimioradio | T.P |
| Immuno Poumon | Etude prospective des facteurs pronostics et prédictifs de l'immunothérapie dans le cancer du poumon | NSCLC | FAb |
| SPECTA | Screening Cancer Patients for Efficient Clinical Trial Access | NSCLC IV naïfs/ thymomes, mésothéliome IV naïfs | T.P |
| Numéro Interne | Etudes | Code | Eudract | Pathologie | Titre | Molécule | Phase | Statut | PI |
| 2018-ONCOHEMA-0228 | ANAM-17-21 | ANAM-17-21 | 2018-002927-40 | Non à petites cellules (NSCLC) | A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of anamorelin HCl for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced non-small cell lung cancer (NSCLC) | Anamorelin HCL | Phase 3 | On hold (Covid) | Colinet Benoît |
| 2018-ONCOHEMA-0159 | PDC-Lung-101 | PDC-Lung-101 | 2018-002382-19 | Non à petites cellules (NSCLC) | An open-label, dose escalation phase I/II study assessing the safety and immunogenicity of PDC*lung, therapeutic cancer vaccine, as single agent or in combination with a checkpoint inhibitor, in patients with Non-Small Cell Lung Cancer (NSCLC) | PDC*lung01 | Phase 1 Phase 2 | Ouverte à l'inclusion | Colinet Benoît |
| 2019-ONCOHEMA-0131 | CodeBreak 200 | 20190009 | 2019‐003582‐18 | Non à petites cellules (NSCLC) | A phase 3 multicenter, randomized, open label, active-controlled, study of AMG 510 versus docetaxel for the treatment of previously treated locally advanced and unresectable or metastatic NSCLC subjects with KRAS p.G12C mutation | AMG 510 | Phase 3 | Ouverte à l'inclusion | Colinet Benoît |
| 2019-ONCOHEMA-0111 | PACIFIC-4 | D9103C00001 | 2018-002572-41 | Non à petites cellules (NSCLC) | A Phase III, Randomized, Placebo-controlled, Double-blind, Multi-center, International Study of Durvalumab Following Stereotactic Body Radiation Therapy (SBRT) for the Treatment of Patients With Unresected Stage I/II, Lymph-node Negative Non-small Cell Lung Cancer (PACIFIC-4/RTOG-3515) | Durvalumab | Phase 3 | Ouverte à l'inclusion | Colinet Benoît |
| 2019-ONCOHEMA-0047 | DRIIV-1 | OX2016-203-01 | 2017-000088-34 | Toutes tumeurs | An Open-label, Dose-escalation Phase I/Ib Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of AsiDNA, a DNA Repair Inhibitor Administered Intravenously, as Single Agent and to Assess the Safety and the Efficacy of AsiDNA in Combination With Carboplatin With or Without Paclitaxel, in Patients With Advanced Solid Tumors | AsiDNA | Phase 1b | Ouverte à l'inclusion | Canon Jean-Luc |
| 2019-ONCOHEMA-0035 | Precision 2 - Afatinib | 1200.264 | 2016-003411-34 | Toutes tumeurs (HER2 mut HER3 mut, EGFR mut excluding non-squamous nsclc) | Precision 2: an open explorative phase II, open label study of afatinib in the treatment of advanced cancer carrying an EGFR, a HER2 or a HER3 mutation followed by the addition of paclitaxel to afatinib at disease progression. | Afatinib | Phase 2 | Ouverte à l'inclusion | Canon Jean-Luc |
| 2019-ONCOHEMA-0093 | Precision 2 – Olaparib | 1-2018 BSMO | 2018-002966-37 | Toutes tumeurs (specific pathogenic genetic alteration (with the exception of BRCA1/2 mutated breast, prostate and pancreatic cancer and HRD ovarian cancer )) | Efficacy of Olaparib in advanced cancers occurring in patients with germline mutations or somatic tumor mutations in homologous recombination genes. | Olaparib | Phase 2 | Ouverte à l'inclusion | Canon Jean-Luc |
| 2018-ONCOHEMA-0205 | Translate | A9001502 | Toutes tumeurs | Treatment resistance following anti-cancer therapies | Prospective - Collection d'échantillons | Ouverte à l'inclusion | Canon Jean-Luc | ||
| 2018-ONCOHEMA-0173 | Tumorbase | ONCOGHDC2017-01 | Toutes tumeurs | Prospective collection of biological samples for translational research on patients with tumoral or hematological diseases (TUMOR-base) | Prospective-Collection d'échantillons | Ouverte à l'inclusion | Carrasco Javier | ||
| 2018-ONCOHEMA-0078 | 01151 | 01151 | Non à petites cellules (NSCLC) Petites cellules (SCLC) | Cardiovascular morbidities and lung cancer treatment: a prospective registry | Observationnelle | Ouverte à l'inclusion | Colinet Benoît | ||
| 2018-ONCOHEMA-0216 | Pacific R | D4194R00005 | Non à petites cellules (NSCLC) | First real-world data study on Unresectable stage III NSCLC Patients treated with durvalumab within the Early Access Program (EAP) after chemoradiotherapy | Durvalumab | Observationnelle | Ouverte à l'inclusion | Colinet Benoît | |
| 2019-ONCOHEMA-0137 | EXCLAIM-2 | TAK-788-3001 | 2019-001845-42 | Non à petites cellules (NSCLC) | Phase III clinical trial evaluating TAK-788 versus platinum-based chemotherapy (pemetrexed/cisplatin or pemetrexed/carboplatin) as first-line treatment for patients with non-small cell lung cancer with EGFR exon 20 insertion mutations. | TAK-788 | Phase 3 | Ouverture prochaine | Colinet Benoît |
| 2020-ONCOHEMA-0014 | Skyscraper 3 | GO41854 | 2019-0044773-29 | Non à petites cellules (NSCLC) | A phase I/III, randomized, double-blind, placebo-controlled study of atezolizumab and tiragolumab compared with durvalumab in patients with unresectable stage III non-small cell lung cancer who have not progressed after concurrent platinum-based chemoradiation | Tiragolumab | Phase 1/2/3 | Ouverture prochaine | Colinet Benoît |
